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Abstract
Genome-wide association studies have been used successfully to detect associations between common genetic
variants and complex diseases, but common single-nucleotide polymorphisms (SNPs) detected by these studies
explain only 5–10% of disease heritability. Alternatively, the common disease/rare variants hypothesis suggests that
complex diseases are often caused by multiple rare variants with moderate to high effects. Under this hypothesis,
the analysis of the cumulative effect of rare variants may thus help us discover the missing genetic variations.
Collapsing all rare variants across a functional region is currently a popular method to find rare variants that may
have a causal effect on certain diseases. However, the power of tests based on collapsing methods is often
impaired by misclassification of functional variants. We develop a data-adaptive forward selection procedure that
selectively chooses only variants that improve the association signal between functional regions and the disease
risk. We apply our strategy to the Genetic Analysis Workshop 17 unrelated individuals data with quantitative traits.
The type I error rate and the power of different collapsing functions are evaluated. The substantially higher power
of the proposed strategy was demonstrated. The new method provides a useful strategy for the association study
of sequencing data by taking advantage of the selection of rare variants.
Background
Genome-wide association studies (GWAS) have been
used successfully to detect associations between com-
mon genetic variants and complex diseases. However,
common single-nucleotide polymorphisms (SNPs)
detected by current GWAS explain only at most 5–10%
of disease heritability [1]. One possible reason could be
that another type of variant, rare variants, has not been
considered in the current GWAS. Recent studies have
shown that common diseases can be caused by func-
tional variants with a wide spectrum of allele frequen-
cies, including rare alleles [2-4]. GWAS on common
SNPs are based on the currently popular common dis-
ease/common variants hypothesis for complex disease
etiology; these studies are well suited for detecting
genetic variants with high allele frequencies and
relatively small to modest genetic effects. There are
some difficulties in identifying variants based on the
alternative common disease/rare variants hypothesis,
which suggests that complex traits are caused collec-
tively by multiple rare variants with moderate to high
effects. Under this hypothesis, the analysis of the cumu-
lative effect of rare variants may become crucial for dis-
covering the missing genetic variation from traditional
GWAS.
With the development of next-generation sequencing
technologies, more rare variants can be genotyped, so
the analysis of associations between rare variants and
diseases becomes possible. It is well known that tradi-
tional GWAS lack power for detecting rare variants.
More powerful tests are needed to analyze resequencing
genetic data. Recently, Li and Leal [5] proposed a strat-
egy that collapses all the rare variants across a func-
tional region. The idea behind this strategy is to assume
that each rare variant in a functional region contributes
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will result in enriched association signals.
Several tests based on different collapsing strategies
for case-control studies have been proposed. One is the
cohort allelic sum test (CAST) [6], in which the number
of individuals with one or more mutations in a group (e.
g., a gene) are compared between case subjects and con-
trol subjects. Because CAST deals only with rare var-
iants, the combined multivariate collapsing (CMC)
method [5] generalized it by performing a multivariate
test with common variants and collapsing scores of rare
variants. A weighted-sum statistic [7] is another method
that collapses both common and rare variants by adding
different weights based on allele frequencies, assuming
that rare variants have a high effect compared with
common variants. With the regression approaches pro-
posed by Morris and Zeggini [8], these methods can
also be extended to quantitative phenotypes. In addition,
the power of a single-marker test is usually low because
of the lack of genetic variant information and the need
to adjust for multiple corrections. Multiple-marker tests
might also lose power as a result of higher degrees of
freedom. The collapsing methods can avoid drawbacks
from both single-marker tests and multiple-marker tests
by considering all the genetic variant information with
only 1 degree of freedom.
However, the collapsing methods may not be robust
and could be seriously impaired by misclassification of
collapsing regions [5]. Regions can usually be defined by
genes, SNP allele frequencies, or variant functionality. If
all rare variants within a collapsing region have the same
positive or negative effect on a disease, then the associa-
tion signal could be amplified; however, if collapsing
combines functional and nonfunctional variants, this
would adversely affect power. To address this problem,
we develop a data-driven forward selection strategy in
which a common variant is first chosen as a base to col-
lapse a specific region and then rare variants are selected
to be collapsed with the base SNP. The proposed method
is well suited for detecting regions in which common and
rare variants have the same genetic effect on a disease,
especially when the association signal of common var-
iants cannot be identified by traditional GWAS. The new
method is robust to the size of the region and can effi-
ciently deal with noise caused by misclassification of non-
causal rare variants. We apply our method to the Genetic
Analysis Workshop 17 (GAW17) unrelated individuals
data with quantitative traits Q1 and Q2. The proposed
method works for quantitative traits.
Methods
Data preprocessing
We analyze the GAW17 unrelated individuals data set,
with 200 replicates of simulated phenotypes Q1 and Q2,
to compare the power of different tests. There are 697
samples consisting of 209 case subjects and 488 control
subjects. The data set contains 24,487 SNPs within
3,205 genes generated using real sequence data from the
1000 Genomes Project. We define rare variants as SNPs
with a minor allele frequency less than 0.01 and perform
collapsing within each gene. Because collapsing methods
do not work well if the region includes too few SNPs,
we first filter the genes according to a criterion of hav-
ing at least 10 variants with one or more common
SNPs. After filtering, we have 553 genes for analysis.
The analysis is performed with the knowledge of the
underlying simulating model.
To control the false-positive rate, we adjust pheno-
types for the effects of confounding variables and popu-
lation stratification. We perform a linear regression of
the phenotypes from the first replicate on the variables
Sex, Age, and Smoking status to select confounding
v a r i a b l e s .T h er e s u l t sa r es h o w ni nT a b l e1 .V a r i a b l e s
with a p-value greater than 0.05 are selected as covari-
ates for the adjustment. The top five eigenvectors from
Eigenstrat [9,10] are also considered covariates. For each
replicate, residuals of the multivariate linear regression
of phenotypes on all the selected covariates are regarded
as the adjusted phenotypes.
Data-adaptive forward selection
In brief, our strategy is as follows. We start with the
most significant common SNP within one region. Rare
variants are then added to the collapsed set one at a
time until there are no variants remaining or until there
is no visible improvement in the goodness-of-fit of the
fitted model. More specifically, assume that there are m
common variants and n rare variants within a certain
predefined genomic region. Let x denote the genotype
for all samples of a certain common variant, and let g
denote the rare variant. Our strategy consists of the fol-
lowing steps.
Step 1. Build a linear model on each common SNP.
The SNP with the largest genetic effect as measured by
the F statistic of the linear regression is selected as the
base of the collapsing function for this region:
Table 1 p-Value for the selection of covariates for Q1 and
Q2
Covariate p-value for Q1 p-value for Q2
Intercept 1.19 × 10
−9 0.149
Age <2 × 10
−16 0.353
Sex 0.564 0.315
Smoke 1.09 × 10
−12 0.329
Age and Smoke are selected as the covariates to adjust the phenotype Q1; no
covariates were used for the adjustment of Q2.
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Step 2. Collapse each rare variant with the base SNP
in this region according to a specific collapsing function.
Perform a linear regression on each collapsed score Col-
lapse(S, gi). Based on the F statistics, variants with the
most significant values are then selected as the base for
the next procedure:
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Step 3. If Fnew >F,t h e nu p d a t eS, F,a n dn with Snew,
Fnew,a n dn − 1. Repeat step 2 until either F no longer
increases or n =0 .
When the selection procedure is finished, the test sta-
tistic FS is defined as:
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which is the absolute value of the t statistics in the
linear regression model:
Ey S () , =+ ab final (6)
where Sfinal is the final collapsed score after the selec-
tion. Under the null hypothesis, the selection procedure
drives the statistics in two different directions; taking
the absolute value allows us to proceed with the nor-
malization step, described in the next subsection.
Genome-wide permutation test
To correct the bias resulting from selection and obtain the
global empirical p-value, we perform a genome-wide per-
mutation test. Assume that M permutations are performed
for k candidate genes. Let FSi be the observed t statistics
for the ith gene, and let FSnull i
j be the observed t statistics
for the ith gene on the jth permutation. To compare the
genetic effect across genes, we normalize the statistics
using the estimated mean and variance from the permuta-
tion and obtain the adjusted statistic FSadji:
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be the maximum value of the observed statistics in the
jth permutation. The global p-value of the ith gene is
the proportion of mj >F S adji:
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Comparison of tests
We investigate the performance of our forward selection
strategy with three collapsing methods: (1) the indicator
method, (2) the sum method, and (3) the weighted-sum
method. Let rij represent the genotype for the ith indivi-
dual at the jth locus. The collapsing functions are then
defined as follows. The indicator function:
fr I r ii j
j
() = ∑ (13)
is a function of the presence or absence of any minor
allele in any region within an individual, which was first
used in CAST [6]. The sum function:
fr r ii j
j
() =∑ (14)
is a function that describes the overall effect at any
region within an individual. It has the same effect as
proportion coding. Both the indicator and sum func-
tions have been demonstrated to be powerful in the
detection of associated rare variants [8]. The weighted-
sum function is:
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and n is the total number of individuals.
We estimate allele frequencies by jointly considering
all subjects, because we could not follow the suggestion
to estimate allele frequencies from unaffected individuals
[7] when dealing with quantitative traits.
The test statistics of the indicator, sum, and weighted-
sum functions without a forward selection strategy are
denoted Tind, Tsum,a n dTws, respectively, and their p-
values can be calculated from the t distribution and
adjusted by the Bonferroni correction. Statistics Tind and
Tsum deal only with the rare variants, whereas Tws con-
siders both common and rare variants.
The corresponding statistics obtained with our for-
ward selection strategy are denoted FSind,F S sum,a n d
FSws. Another test statistic, denoted Tcom,i sa l s o
obtained by using linear regression on the most signifi-
cant common variant in a region. A comparison of the
proposed strategy with Tcom allows us to access the
effect of adding rare variant information to common
variant information in a specific genetic region.
Results
Type I error and power
We analyzed 553 filtered genes on the 200 replicates for
phenotypes Q1 and Q2. The type I error rate of the test
and the power of the test are defined as follows. Take Q1
as an example; there are 4 functional and 549 nonfunc-
tional genes. At a given significance level a, if the adjusted
or global p-value for a gene is greater than a,w ew o u l d
reject the null hypothesis. Next, we consider (number of
tests that rejected the null hypothesis)/[200(549)] for the
549 nonfunctional genes as the type I error rate of the
test. Because different tests should adapt to different types
of genes, power is calculated by (number of tests rejected
at the null hypothesis)/200 for each functional gene.
We found that the type I error of tests using the
weighted-sum function was inflated for Q1. To have a
fair comparison, we selected a different significance level
for each test to have the type I error rates of all tests at
the same level. Some permutation tests cannot have
exact 5% type I error because there were only 1,000 per-
mutations. Therefore we chose a significance level so
that all tests had a well-controlled false-positive rate of
about 6% for Q1 and 5% for Q2 (Table 2). The power
of the tests was calculated based on the same signifi-
cance levels as the type I error. Table 3 lists all the
genes with power greater than 5% according to at least
one test.
For Q1, FTL1 was detected by Tcom with 100% power,
which indicated that the common SNP had a strong
effect on the disease. However, Tcom is not optimal for
evaluating the proposed strategy. Gene KDR is the case
we want to consider, because Tcom became underpow-
ered, which indicated that the effects of common SNPs
were not significant. For KDR,F S ws achieved the highest
power, followed by Tws,F S sum, and FSind. We also found
that tests considering both common and rare variants
achieved higher power than those that considered only
rare variants (Tind and Tsum) or common variants
(Tcom). All forward-selection-based tests were ranked at
the top for KDR, which demonstrates the potential
power of the forward selection strategy. For Q2, all tests
became underpowered. Three genes (SREBF1, SIRT1,
and VNN3) were detected by at least one test with
power greater than 5%. FSws achieved the highest power
(8%) in detecting SIRT1.
Discussion
We have proposed a data-adaptive forward selection
strategy for genetic association studies with multiple
common and rare variants. The proposed test is aimed
at selecting rare variants for collapsing that best amplify
the association signal between functional regions and
phenotypes. Traditional collapsing methods do not have
the option of selectively collapsing only functional rare
variants with the same effects on the risk of disease;
thus they may be underpowered by misclassification in
collapsing regions. The major advantage of our method
is that it can selectively collapse rare variants with the
same genetic effect as the common variant in the
Table 2 Significance level (a) and type I error rate for Q1
and Q2
Trait Tind Tsum Tws FSind FSsum FSws Tcom
Q1: a 0.042 0.038 0.0171 0.052 0.035 0.003 0.038
Q1: type I 6% 6% 6% 5.5% 6% 6% 6%
Q2: a 0.041 0.03 0.103 0.06 0.054 0.083 0.053
Q2: type I 5% 5% 5% 5% 5% 5% 5%
Tind, Tsum, and Tws use adjusted p-values by the Bonferroni correction; FSind,
FSsum,F S ws, and Tcom use the global permutation p-value. The power of tests
is calculated on the basis of the same significance levels as the type I error.
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association signal. To correct the bias resulting from
selection and to alleviate the computational burden, we
performed a genome-wide permutation test. We evalu-
ated the power of our method using different collapsing
functions, based on the same type I error. The results
show that the proposed method has substantially higher
power across different collapsing strategies. The way to
select rare variants for each functional region also sug-
gests that our method may have higher power to detect
functional regions with an either positive (damage) or
negative (protective) effect on the disease traits, even if
no common variant is associated with the disease, so
long as enough rare variants collectively affect the dis-
ease. The forward selection strategy could also be a
powerful tool by adding different weights based on allele
frequencies in order to lower the effect of common
variants.
Conclusions
We developed a data-adaptive forward selection proce-
dure by collapsing a common variant with selected rare
variants. The validity and substantially higher power of
the proposed strategy were demonstrated using the
GAW17 data. The method provides a useful strategy for
association studies of sequencing data by taking advan-
tage of the selection of rare variants.
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Table 3 Power of seven tests for Q1 and Q2
Phenotype Gene Tind (%) Tsum (%) Tws (%) FSind (%) FSsum (%) FSws (%) Tcom (%)
Q1 FTL1 5 9.5 80.5 95 99.5 71 100
KDR 2 4 21 9.5 15.5 28 1.5
Q2 SREBF1 5 6 2 0 0 0.5 0
SIRT1 1 2.5 7.5 0 0.5 8 0
VNN3 0 0 1 6 5.5 4 2.5
Tind, Tsum, and Tws are tests of collapsing-function-based linear regression without the forward selection procedure, and FSind,F S sum,a n dF S ws are forward-
selection-based tests. Collapsing functions include the indicator, sum, and weighted-sum functions. The power of tests is calculated on the basis of the same
significance levels as the type I error.
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